Drugs / Rabies vaccine
Rabies vaccine
Trials 12
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 24 trials · 1 missed | ||||||
| Phase 2 | NCT07445815 | Jan → Jul 2026 overdue | — | Lanzhou Institute of Biological Products Co., Ltd | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06799234 | Jul 2025 → Mar 2026 overdue | Rift valley fever | University of Oxford | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03276962 | Sep 2017 → Nov 2019 | malaria | GlaxoSmithKline | Completed | Missed primary |
| Phase 2 | NCT02276625 | Oct 2014 → Feb 2016 | rabies | Leiden University Medical Center | Unknown | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT07455318 | May 2026 → Jun 2027 expected | — | Institute of Tropical Medicine, Belgium | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07055893 | Mar 2026 → Jan 2027 expected | — | Sinovac Biotech Co., Ltd | Not yet recruiting | No outcome recorded |
| Phase 44 trials | ||||||
| Phase 4 | NCT05453487 | Jul → Oct 2022 | COVID-19, rabies | China National Biotec Group Company Limited | Unknown | No outcome recorded |
| Phase 4 | NCT02564471 | Nov 2016 → Aug 2018 | rabies | State University of New York - Upstate Medical University | Completed | No outcome recorded |
| Phase 4 | NCT02374814 | Mar 2015 → Sep 2016 | rabies | State University of New York - Upstate Medical University | Completed | No outcome recorded |
| Phase 4 | NCT01173302 | May → Aug 2010 | rabies | Peking University People's Hospital | Unknown | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT02547727 | Feb 2016 → Dec 2023 | rabies | Queen Saovabha Memorial Institute | Unknown | No outcome recorded |
| — | NCT01641315 | Sep 2015 → Apr 2018 | rabies | Queen Saovabha Memorial Institute | Completed | No outcome recorded |
| Comparator or background therapy18 trials | ||||||
| Phase 1 | NCT07342257 Background | Nov 2024 → May 2025 | rabies | Synermore Biologics (Suzhou) Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT00703066 Comparator | Jun 2008 → Jul 2009 | malaria | African Malaria Network Trust | Unknown | No outcome recorded |
| Phase 1/2 | NCT04495569 Background | Feb → Jun 2019 | rabies | Synermore Biologics (Suzhou) Co., Ltd. | Completed | No outcome recorded |
| Phase 1/2 | NCT01635647 Comparator | Nov 2012 → Aug 2014 | malaria | University of Oxford | Completed | No outcome recorded |
| Phase 2 | NCT03961555 Background | Sep 2019 → Dec 2021 | rabies | Synermore Biologics Co., Ltd. | Completed | Met primary |
| Phase 2 | NCT01658696 Comparator | Aug 2012 → Feb 2013 | malaria | University of Oxford | Completed | No outcome recorded |
| Phase 2 | NCT01666925 Comparator | Mar → Aug 2012 | malaria | University of Oxford | Completed | No outcome recorded |
| Phase 2 | NCT00460525 Comparator | May 2007 → Jul 2009 | Plasmodium falciparum malaria | U.S. Army Medical Research and Development Command | Completed | Missed primary |
| Phase 2 | NCT00703521 Comparator | Aug → Oct 2002 | rabies | Mahidol University | Completed | No outcome recorded |
| Phase 2 | NCT00031070 Background | ? → Dec 2006 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2/3 | NCT07345208 Comparator | Dec 2025 → May 2027 expected | rabies | International Centre for Diarrhoeal Disease Research, Bangladesh | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT05846568 Background | Oct 2022 → Sep 2023 | rabies | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT04704830 Background | Apr 2021 → Mar 2023 overdue | Plasmodium falciparum malaria | University of Oxford | Active not recruiting | Met primary |
| Phase 3 | NCT04644484 Background | Sep 2020 → Jun 2022 | Rhabdoviridae infectious disease, rabies | Synermore Biologics (Suzhou) Co., Ltd. | Completed | Met primary |
| Phase 3 | NCT02177032 Comparator | Jun → Oct 2014 | rabies | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT01466387 Comparator | Nov 2011 → Apr 2012 | Japanese encephalitis, meningococcal meningitis, rabies, typhoid fever +1 | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00345319 Comparator | Mar → May 2006 | rabies | Novartis Vaccines | Completed | No outcome recorded |
| Phase 4 | NCT03557008 Comparator | Jul 2018 → Jun 2022 | rabies | Emory University | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2026-08-06 | Sinovac Biotech Co., Ltd | Regulatory 科兴冻干人用狂犬病疫苗获药品注册证书 sinovac.com ↗
2026年8月6日，北京科兴控股（集团）有限公司旗下科兴（成都）生物制品有限公司研制的冻干人用狂犬病疫苗（Vero细胞）获得国家药品监督管理局颁发的《药品注册证书》（批准文号：国药准字S20260060）。 |
| 2025-02-07 | Replicate Bioscience | Results Replicate Bioscience Announces Publication of First-in-Human Data for Its Optimized srRNA Rabies Vaccine in Nature Communications replicatebioscience.com ↗
The Phase I study showed that a single dose of RBI-4000 elicited immune responses that attained a World Health Organization (WHO)-established immune threshold of protection against rabies across all dose levels tested, with good tolerability. |
| 2024-02-13 | Replicate Bioscience | Results Replicate Bioscience Announces Positive Initial Clinical Results for its Next Generation srRNA Technology replicatebioscience.com ↗
Replicate Bioscience, a clinical-stage company pioneering novel self-replicating RNA (srRNA) technology to expand applications of RNA vaccines and other treatments, today shared positive results from the Phase 1 trial of RBI-4000, its srRNA-based rabies vaccine. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-08-06 | Sinovac Biotech Co., Ltd | 科兴冻干人用狂犬病疫苗获药品注册证书 sinovac.com ↗ |
| 2025-02-07 | Replicate Bioscience | Replicate Bioscience Announces Publication of First-in-Human Data for Its Optimized srRNA Rabies Vaccine in Nature Communications replicatebioscience.com ↗ |
| 2024-02-13 | Replicate Bioscience | Replicate Bioscience Announces Positive Initial Clinical Results for its Next Generation srRNA Technology replicatebioscience.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 32 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rabies vaccine | “purified chick-embryo cell-culture rabies vaccine” NCT07455318 ↗ |
| Known as | Abhayrab | “licensed rabies vaccine [Abhayrab]” PMID 38310910 ↗ Feb 2024 |
| Known as | ChengDa rabies vaccine | “Our findings demonstrate that the ChengDa rabies vaccine offers an alternative with a high degree of efficacy and yet limited side effects and ensures that the exposed patient...” PMID 21752947 ↗ Jul 2011 |
| Known as | PCEC rabies vaccine | “12 doses of the PCEC rabies vaccine, administered ID (0.1mL for each injection)” NCT02177032 ↗ |
| Modality | Vaccine | “Rabies Vaccine” NCT00031070 ↗ |
| Route | Intramuscular | “Rabies vaccine 1.0 mL IM on day 0, 7, 28,and 1 year” NCT00703521 ↗ |